Skip to main content
PMC home page
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2020 Aug 14;10:1424. doi: 10.3389/fonc.2020.01424

Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets

Nan Wei 1,2, Yong'an Song 1,2, Fan Zhang 1, Zhifu Sun 3,*, Xiaoju Zhang 1,*
PMCID: PMC7456826  PMID: 32923394

Abstract

Background: Targeted therapy for lung cancer with epidermal growth factor receptor (EGFR) mutations with tyrosine kinase inhibitors (TKIs) represents one of the major breakthroughs in lung cancer management. However, gradually developed resistance to these drugs prevents sustained clinical benefits and calls for resistant mechanism research and identification of new therapeutic targets. Acquired T790M mutation accounts for the majority of resistance cases, yet transcriptome changes in these cells are less characterized, and it is not known if new treatment targets exist by available drugs.

Methods: Transcriptome profiling was performed for lung cancer cell line PC9 and its resistant line PC9GR after long-term exposure to gefitinib through RNA sequencing. Differentially expressed genes and changed pathways were identified along with existing drugs targeting these upregulated genes. Using 144 lung cancer cell lines with both gene expression and drug response data from the cancer cell line encyclopedia (CCLE) and Cancer Therapeutics Response Portal (CTRP), we screened 549 drugs whose response was correlated with these upregulated genes in PC9GR cells, and top drugs were evaluated for their response in both PC9 and PC9GR cells.

Results: In addition to the acquired T790M mutation, the resistant PC9GR cells had very different transcription programs from the sensitive PC9 cells. Multiple pathways were changed with the top ones including TNFA signaling, androgen/estrogen response, P53 pathway, MTORC1 signaling, hypoxia, and epithelial mesenchymal transition. Thirty-two upregulated genes had available drugs that can potentially be effective in treating the resistant cells. From the response profiles of CCLE, we found 17 drugs whose responses were associated with at least four of these upregulated genes. Among the four drugs evaluated (dasatinib, KPT-185, trametinib, and pluripotin), all except trametinib demonstrated strong inhibitory effects on the resistant PC9GR cells, among which KPT185 was the most potent. KPT-185 suppressed growth, caused apoptosis, and inhibited migration of the PC9GR cells at similar (or better) rates as the sensitive PC9 cells in a dose-dependent manner.

Conclusions: Acquired TKI-resistant lung cancer cells (PC9GR) have dramatically changed transcription and pathway regulation, which expose new treatment targets. Existing drugs may be repurposed to treat those patients with developed resistance to TKIs.

Keywords: lung adenocarcinoma, EGFR mutation, gefitinib, drug resistance, RNA sequencing, KPT-185, dasatinib

Introduction

Lung cancer is the leading cause of cancer deaths around the world with staggering 15% of five-year survival rates. Non-small cell lung cancer (NSCLC), consisting mainly of lung adenocarcinoma and squamous cell carcinoma, represents about 85% of all lung cancer cases (1). The most effective treatment is surgical removal for early stage NSCLC; however, most patients are diagnosed at late stages when the mainstays of treatments are chemotherapy and radiotherapy. Due to the side effects and low efficacy of these treatments, targeted therapies for patients with certain gene mutations have become an appealing alternative (2), among which mutations in EGFR and EML4-ALK translocation are two typical examples and routinely tested to guide clinical treatment selections. Both EGFR and EML4-ALK mutations are mainly seen in lung adenocarcinoma, and these activated oncogenic mutations promote cell survival, proliferation, invasion, and metastasis (3, 4). Abolishment of their activities through TKIs may inhibit tumor growth and lead to tumor shrinkage and complete response in some of the patients with EGFR mutations (5–8). The major challenge in the clinic, however, is gradually developed resistance to these TKIs (9, 10), and an alternative drug targeting new mutations or a next-generation TKI is generally needed to maintain treatment effectiveness. Understanding the mechanism of acquired resistance is critical to identify new targets and develop new treatment strategies.

Several TKI-resistant mechanisms have been proposed. It has been observed that 50–60% of those with subsequent TKI resistance develop a secondary mutation T790M (10–13). Other acquired single nucleotide mutations include D761Y, T854A, and L747S in EGFR (14, 15). Gene amplification is also reported for MET (16, 17), HER2 (18), and MAPK (19). For tumors without acquired or primary resistant mutations, abnormal epigenetic regulation may be in play (20, 21). Resistant tumors may have an epithelial-to-mesenchymal transition (EMT) phenotype with accompanying high expression of vimentin or fibronectin (22–24) or N-cadherin (25); AXL or GAS6 activation promotes cell proliferation, migration, and invasion in cancer (26, 27); and activated NF-κB pathway (28) and IGF1-R pathway are also reported with TKI resistance (29).

Although T790M mutation is the major resistant mechanism, transcriptome changes in these cells are not well-characterized. We hypothesized that the resistant cells had very different transcription programs and may expose new treatment targets with existing drugs to overcome the resistance. To test the hypothesis, we used an EGFR-mutant PC9 lung cancer cell line that is highly sensitive to TKIs initially and developed a stable drug-resistant cell line PC9GR after long-term exposure to gefitinib. Through an RNA sequencing (RNA-seq) experiment, we profiled the genetic and transcriptome differences between the resistant and sensitive cell lines to getitinib. The acquired resistant cell line PC9GR obtained the well-known T790M mutation, but more noticeably, it had dramatically changed transcriptome programs and regulation pathways. Combined with CCLE gene expression and drug response data, we have identified several available drugs that can be potentially used to treat the resistant cells or tumors.

Materials and Methods

Cell Lines

Human lung cancer PC9 and PC9GR cell line generation were described in our previous work (30). The PC9 was derived from lung adenocarcinoma and is inherently sensitive to TKIs, such as gefitinib and erlotinib. Genetically, it harbors a canonical 15 base deletion at exon19 of EGFR. The established resistant PC9GR was obtained after long-term exposure to gefitinib with over 260-fold higher resistance than its parental PC9 cells.

Both PC9 and PC9GR were verified for their authentication with ATCC PC9 profile through STR test using nine markers (Shanghai Biowing Biotechnology, Shanghai, China).

RNA Sequencing and Data Analysis

The library preparation, sequencing, and initial data preprocessing were described previously (30). Quantified raw gene count was normalized through fragments per kilobase million (FPKM) and then log2 transformed for further analysis. Differential expression between PC9GR and its parenting PC9 cells was conducted by R package limma (31). Genes that have a false discovery rate (FDR) <0.05, log2 fold change >1 (2-fold), and minimum mean expression across all samples (in FPKM) >1 were considered as differentially expressed genes (DEGs). Pathway or gene set enrichment analysis was performed for these DEGs by rapid integration of term annotation (RITAN) (32), and those with FDR >0.05 were considered as significantly enriched. As HiSAT2 does not map sequence reads with short insertion/deletion (indels) well (33), we further performed two-step alignment by spliced transcript alignment to a reference (STAR) (34), and the alignment from this was used for indel detection.

Identification of Drugs That Target Upregulated Key Genes in PC9GR-Resistant Cells

To identify existing drugs that can potentially be used to treat gefitinib-resistant lung cancer cells, we used ingenuity pathway analysis (IPA) gene annotations for which an available drug was provided to select the DEGs that were unregulated in PC9GR cells. To get more evidence of an available drug that may indeed be effective and act on the intended target gene, we further analyzed the gene expression and drug response data from CCLE (https://portals.broadinstitute.org/ccle/about), and CTRP (https://portals.broadinstitute.org/ctrp). Processed and normalized RNA sequencing data for 1,076 cell lines in RPKM were downloaded, and then data for lung cancer cell lines (n = 189) were extracted. Drug response data for 545 drugs and 886 cell lines were downloaded, and lung cancer cell lines with both RNA-seq and drug response data (n = 144) were used for correlation analysis between expression of DEGs that were upregulated and with drugs whose response data were tested in CTRP. The drug and gene pairs with correlation coefficient <-0.3 and significant p < 0.001 were kept for further investigation.

Evaluation of Treatment Response to Selected Drugs

Cell Viability Assay

PC9 and PC9GR cells in logarithmic growth stage were seeded in 96-well plates at a density of 3,000 cells per well and grown overnight. The next day, the growth medium was replaced with fresh media with dasatinib (MedChemExpress, Monmouth Junction, NJ, USA), pluripotin (MedChemExpress, Monmouth Junction, NJ, USA), trametinib (MedChemExpress, Monmouth Junction, NJ, USA), and KPT-185 (MedChemExpress, Monmouth Junction, NJ, USA), respectively, by the gradient dilution method. After being incubated for 72 h, Cell Counting Kit 8 (APExBIO, Houston, Texas, USA) was added for an additional 2 h of incubation at 37°C. Cell viability was determined by measuring the absorbance at 450 nm in a microplate reader (Thermo, Waltham, MA, USA).

Colony Formation Assay

PC9 and PC9GR cells in logarithmic growth stage were seeded in six-well plates at a density of 3,000 cells per well and grown overnight. The next day, the growth medium was replaced with fresh media with multiple dilution concentrations of KPT-185 at 37°C for 9 days. The medium was then discarded, washed with PBS three times, and fixed with 4% paraformaldehyde for 2 h. After staining with 0.1% crystal violet for 30 min, the colonies were visualized and photographed.

Flow Cytometric Apoptosis Assay

PC9 and PC9GR cells in logarithmic growth stage were seeded in six-well plates at a density of 2 × 105 cells per well and grown overnight. The next day, the growth medium was replaced with fresh media with multiple dilution concentrations of KPT-185 at 37°C for 48 h. The cells from both suspension and adherence were collected and resuspended in binding buffer containing Annexin V-fluorescein isothiocynate (FITC). Staining solution with propidium iodide (PI) was then added following the kit instructions, and localization of Annexin V and PI for apoptotic cells was performed by FACS cytometry (BD Biosciences, Franklin Lakes, NJ, USA) and percentage of apoptotic cells were obtained.

Wound Healing Assay

PC9 and PC9GR cells in logarithmic growth stage were seeded in six-well plates at a density of 4 × 105 cells per well and grown overnight. The next day, the cell layer was wounded with a yellow pipette tip, and floating cells were washed with PBS. Then, 2% FBS medium containing KPT-185 (0.25, 0.5, 1, and 2 μM) was added into each well. After incubating for 0 and 48 h, three randomly chosen fields were analyzed for each well, and cell migration rate was calculated relative to control well-without KPT-185.

All data analyses were conducted in R 3.5.2 (https://www.r-project.org/) or otherwise stated. The raw and processed RPKM data was deposited into GEO with accession number GSE129221 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129221).

Results

Phenotypic Characteristics of PC9 Gefitinib-Resistant Cells

After 1 year of gefitinib treatment, we successfully established a gefitinib-resistant NSCLC cell line PC9GR from the gefitinib-sensitive PC9 cell line. The IC50 value for gefitinib in PC9GR cells was 5.311 ± 0.455 μM, which is 265-fold higher than that in PC9 cells (0.020 ± 0.003 μM) as we previously reported (30). From RNA-seq of these cell lines, we confirmed that both PC9 and PC9GR cells had 15-base deletion on exon 19 of EGFR. However, the PC9GR cells obtained a newly developed T790M mutation (Figure 1A), mimic to the clinical observation that an initial sensitive tumor develops resistance to gefitinib. This mutation is known to be the most common reason in the clinic for patients who develop TKI resistance after treatment (10, 35, 36). No other reported mutations reported previously (D761Y, T854A, and L747S) (14, 15) were found in the PC9GR cells.

Figure 1.

Figure 1

Open in a new tab

Mutation and gene expression profiles of PC9 and resistant PC9GR cells. (A) IGV view of EGFR gene from RNA-seq sequence reads showing acquired T790M mutation in the PC9GR cells (marked as C1, C2, C3 in the IGV tracks), which is absent in parental PC9 cells (marked as A1, A2, A3). (B) Principal component analysis for PC9 and PC9GR cells. Component 1 accounts for 82% of variance, and resistant cells have quite different expression profiles from PC9 cells. (C) Volcano plot of differential expression analysis between PC9GR and PC9 cells. Red highlights are genes with false discovery rate <0.05 and fold change >2 (either higher or lower in PC9GR cells). The green numbers on the top are the number of down (469) and up (396) regulated genes in PC9GR cells.

Distinct RNA Expression Profiles Between PC9GR and PC9 Cells

We first conducted principal component analysis (PCA) for the RNA-seq samples from PC9 and PC9GR cells and found that they formed very distinct clusters, and the first principal component explained over 82% of variance, a clear indication that they had very different expression profiles in addition to the T790M mutation (Figure 1B). Differential expression analysis identified 865 DEGs (396 up- and 469 down-expressed, Figure 1C and Table S1) at FDR < 0.05, log2 fold change >1, and minimum mean expression across samples in FPKM > 1. The vast majority of these DEGs were protein-coding genes (712 out of 865, 82.3%); however, there were many other differentially expressed RNAs, particularly lncRNAs and pseudogenes (Figure 2A). Twenty-eight MSigDB pathways were significantly enriched at FDR < 0.05 although only one was in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways at this stringent cutoff (Figures 2B,C). The most notable ones were TNFA_signaling_via_NFKB, androgen/estrogen response, P53_pathway, MTORC1_signaling, hypoxia and epithelial_mesenchymal_transition. NF-κB is reported to be activated early in response to EGFR targeted therapy by TKIs (37). Epithelial-to-mesenchymal transition is known to be involved in late obtained T790M-associated drug-resistant PC9 cells (PC9GR3) (38). Many of these DEGs are among the upregulated genes previously reported after resistance development to erlotinib (37) or gefitinib (38) (Figure 3A).

Figure 2.

Figure 2

Open in a new tab

Differentially expressed genes (DEG) and enriched gene sets and pathways. (A) DEG distribution by gene class. Protein coding is the most and lincRNA is the second. (B) Significantly enriched gene sets from MSigDB. (C) Significantly enriched KEGG pathways.

Figure 3.

Figure 3

Open in a new tab

Comparison of differentially expressed genes with those reported in the literature. (A) Heat map of DEGs vs. other reports (38) or GEO databases (GSE75602, GSE65420, GSE73189). Genes on the row are DEGs from this study, and columns are gene sets reported from other studies. The first two columns are the most relevant, the genes upregulated after drug resistance to Erlotinib and Gefitinib. (B) The change of reported genes from the literature [AXL/GAS6 (26, 27), CDH1 (39), ERBB2 (18), MAPK1 (19), MET (16), VIM (22–24), NFKB1 (28), and KDM5A (29)] in our study. X-axis is log2 fold change between PC9GR vs. PC9. Y-axis is negative log10 p-value. Horizontal dashed line is p value 0.05, and two vertical dashed lines are for fold change less and larger than 1.5-fold, respectively. Only AXL is dramatically up-expressed. (C–E) are IGV view of gene expression for AXL, LOC339539, and BASP1. Sample names A1-A3 in the IGV tracks are parental PC9 cells and C1-C3 are for PC9GR cells.

Previous studies reported that AXL/GAS6 (26, 27), CDH1 (39), ERBB2 (18), MAPK1 (19), MET (16), VIM (22–24), NFKB1 (28), and KDM5A (29) were increased in TKI-resistant cells. In these data, we only found AXL was increased dramatically with 2.14-fold change and FDR < 0.05. MAPK1, VIM, GAS6, NFKB1, and KDM5A were all slightly increased, and CDH1, ERBB2, and MET had not much change (Figure 3B). As a contrast to AXL (Figure 3C), the top two upregulated genes AL512353.2 (also named LOC339539, Figure 3D) and BASP1 (Figure 3E) had over 8-fold increase.

Candidate Drugs That Can Potentially Be Effective in Treating Resistant PC9GR Cells

Among the upregulated DEGs, 31 had known available drugs potentially targeting these genes (Table S2). We analyzed the expression correlation of these genes with drug response profiles using CCLE and CTRP data sets for 144 lung cancer cell lines. Among 31 genes, we found 20 genes with at least one drug significantly correlated with drug responsiveness (p < 0.001 and correlation R <-0.3) for 160 out of 545 drugs. We then focused on these drugs whose response was negatively correlated with at least four of these genes as shown in Figure 4A. Most of these drugs are used for other cancers or diseases. For example, Dasatinib is a selective tyrosine kinase receptor inhibitor being used to treat chronic myelogenous leukemia (CML) positive for the Philadelphia chromosome. The expression of seven genes (out of 20 upregulated DEGs in PC9GR cells) was correlated with the response to this drug, and administration of the drug may reverse cell resistance to gefibinib as an alternative treatment. Among the negatively correlated genes, AXL expression is known to be associated with TKI resistance and is emerging as a new treatment target (40, 41). Higher expression of this gene was correlated with a better response to Dasatinib in lung cancer cell lines (Figure 4B). CD274 (PD-L1) is an adaptive immune response suppressor and blockade of PD1/PD-L1 represents a major cancer treatment breakthrough. Similarly, higher expression of CD274 was an indicator for better response to Dasatinib (Figure 4B). As another example, KPT-185 is a CRM1 inhibitor, a protein that mediates the nuclear export of proteins, rRNA, snRNA, and some mRNAs. The expression of six upregulated genes in PC9GR cells (Figure 4A) was significantly correlated with the response to KPT-185, such as KCNH2 and FYN (Figure 4C).

Figure 4.

Figure 4

Open in a new tab

Upregulated genes and targeting drugs from combination analysis of our, CCLE, and CTRP data. (A) Top 17 drugs whose response is negatively correlated with at least four upregulated genes in PC9GR cells as indicated in green “light.” Red ones are those not significantly correlated pairs. (B) Scatterplot between Dasatinib response (y-axis, AUC% representing percentage of area under the curve) and gene expression of selected genes (AXL and CD274 on x-axis, which is log2 RPKM value) in 142 lung cancer cell lines of CCLE. Higher expression of both genes is significantly correlated with better response (smaller area under the curve or AUC). (C) Scatterplot between KPT-185 response (y-axis, AUC% representing percentage of area under the curve) and gene expression of selected genes (KCHN2 and FYN on x-axis, which is log2 RPKM value) in 142 lung cancer cell lines of CCLE. Higher expression of both genes is significantly correlated with better response (smaller area under the curve or AUC).

Gefitinib-Resistant PC9GR Cells Respond to Dasatinib, KPT-185, and Trametinib

Among the top five drugs whose response was correlated with the highest number of upregulated genes in the CCLE lung cancer cell lines, Dasatinib, KPT-185, and trametinib are available to purchase for evaluation (Avicin D is an extracted chemical from plants, and LY2183240 is a potent inhibitor of Cannabinoid absorption). We also added pluripotin as its response was associated with expression of AXL and CD274. As shown in Figure 5, all four drugs except trametinib demonstrated significant inhibition effects on both PC9 and PC9GR cells although PC9 cells generally were more sensitive. However, the effect of KPT-185 on resistant PC9GR cells was almost the same or better than on PC9 cells. Further experiments on KPT-185 showed that it significantly suppressed cell growth (Figure 6A) and induced apoptosis of PC9GR cells at the similar or better rates (at lower concentrations, Figure S1) as the PC9 cells in a concentration-dependent manner (Figures 6B–D). KPT-185 also significantly reduced the cell migration of PC9 and PC9GR cells (Figures 6E–G).

Figure 5.

Figure 5

Open in a new tab

Dose and response curves of PC9 and PC9GR cells to Dasatinib, plurpotin, trametinib, and KPT-185. PC9 and PC9GR cell are treated with Dasatinib (A), plurpotin (B), trametinib (C), and KPT-185 (D) at doubling dose for 72 h. Cell viability (y-axis) is detected by CCK-8 assay. KPT-185 is the strongest inhibitor for both PC9 and PC9GR with IC50 0.016 and 0.017, respectively.

Figure 6.

Figure 6

Open in a new tab

The proliferation inhibition, apoptotic induction, and antimigration effect of KPT-185 on PC9 and PC9GR cells. (A) The representative images of colony formation by PC9 and PC9GR cells after being treated with KPT-185 at 0, 0.125, 0.25, 0.5 μM for 9 days. The inhibition is dose dependent and similar between PC9 and PC9GR cells. (B) Quadrant graphs of cell apoptosis analysis for PC9 and PC9GR after being treated with KPT-185 at five concentrations for 48 h using flow cytometry. X-axis represents Annexin V-FITC, and y-axis represents PI. Q1, Q2, Q3, and Q4, respectively, represent dead cell fragments, late apoptosis, early apoptosis, and normal cell community. (C) The ratios of apoptotic cells at different concentrations in PC9 cells. (D) The ratios of apoptotic cells at different concentrations in PC9GR cells. (E) The representative images of migration inhibition after KPT-185 treatments in PC9 and PC9GR cells by wound-healing assay (magnification at 100X). (F) The bar plot of migration inhibition rates at 0, 0.25, 0.5, 1, and 2 uM in PC9 cells. (G) The bar plot of migration inhibition rates at 0, 0.25, 0.5, 1, and 2 uM in PC9GR cells. The bar height represents mean ± SEM of three independent experiments (n = 3, **P < 0.01, ***P < 0.001 compared to controls).

Discussion

Lung adenocarcinoma with EGFR mutations (primarily exon 19 deletions and L858R substitution in exon 21) is sensitive to targeted therapy by TKIs, such as gefitinib and erlotinib, which offers significant survival benefit to patients. Such therapy is better tolerated than traditional chemotherapies. However, eventually developed resistance to these drugs is a major clinical challenge. Although the majority of these resistant tumors are explained by subsequent T790M mutation, how this mutation causes resistance and what other genomic abnormalities occur are not well-characterized. Understanding of the mechanisms helps identify new targets and develop new therapeutic strategies.

In this study, we profiled the transcriptomes before and after PC9 lung cancer cells obtained resistance to gefitinib with development of traditional T790M mutation and found that over 20% of genes (6,699 out of 31,290) were highly differentially expressed at stringent criteria. T790M is considered as a gatekeeper mutation, which does not directly block inhibitor binding to the active site of EGFR but increases its affinity for ATP so that a TKI is outcompeted for its reduced anti-EGFR activities. The dramatically changed transcriptome suggests the resistant mechanism of PC9GR cells was far more complex, and the combination of additional mutations and long exposure to TKIs may led to PC9GR cells' transcriptome reprograming and metabolic changes to adapt their survival. Multiple pathways were changed, and the most noticeable ones were TNFA_signaling_via_NFKB, androgen/estrogen response, P53_pathway, MTORC1_signaling, and hypoxia and epithelial_mesenchymal_transition. NF-κB activation was observed as an early event of resistance development with increased expression of NFKB1 (42). Both TNF and hypoxia were related to adaptive resistance of non-small cell lung cancer cells as reported previously (43). Epithelial-to-mesenchymal transition is also known to be involved in late obtained T790M-associated drug-resistant PC9 cells (PC9GR3) (38).

Our search for new treatment targets found that several existing drugs used for other cancers or diseases may be repurposed to treat those lung cancer patients with acquired resistance to gefitinib. Dasatinib is a selective tyrosine kinase receptor inhibitor used to treat CML. Recent studies have shown that lung cancer with increased YES1 was more responsive to Dasatinib (44), and increased expression of YES1 was reported to be one of the acquired resistant mechanisms to EGFR inhibitors in lung cancer with EGFR mutations (45). Our data is consistent with the reports as YES1 was upregulated in PC9GR cells by 1.5-fold, and these resistant cells were responsive to Dasatinib. KPT-185 is a CRM1 inhibitor, a protein that mediates the nuclear export of proteins, rRNA, snRNA, and some mRNAs. KPT-185 significantly inhibits cancer cell proliferation and induces cell-cycle arrest and apoptosis, such as cancer cells from acute myeloid leukemia (46), pancreatic cancer (47) and NSCLC, including EGFR-TKI-resistant cell lines (48). Our data showed that KPT-185 could inhibit proliferation and induce apoptosis of both PC9GR and PC9 cells yet had a stronger effect causing apoptosis of PC9GR cells at lower concentrations of 0.5 and 1 μM (Figure S1), which can be important as a loose dose is less toxic and desired for human administration.

In addition to KPT-185, there are several other CRM1 inhibitors in various phases of development and applications, which include KPT-249, KPT-251, KPT-276, KPT-330 (Selinexor), KPT-335 (Verdinexor), and KPT-8602 (Eltanexor) (https://www.selleckchem.com/crm1.html) (49). These small-molecule drugs are selective inhibitors of nuclear export (SINEs) that covalently bind to Cysteine 528 residue of CRM1 in a slowly reversible fashion for their anticancer activities. Preclinical and clinical studies have demonstrated their efficacies on a number of solid and hematologic cancers (50). Although our study focused on KPT-185 as it is the drug with response profiles in the CRTP database, the results or conclusions may be applicable to other drugs in the family considering their similar mechanism of actions. In fact, for clinical application, a drug such as KPT-330 may be preferable because of its better bioavailability, mild side effects, and approval for clinical usage (relapsed refractory multiple myeloma). Studies also demonstrate its synergistic effect with cisplatin (51). A multicenter phase I/II clinical trial of selinexor with docetaxel in treating KRAS-mutant NSCLC is being conducted (https://clinicaltrials.gov/ct2/show/NCT03095612). A combination of CRM1 inhibitors with EGFR-TKIs or other drugs as a third- and fourth-line treatment warrants further investigation for TKI-resistant tumors.

Pluripotin is a small molecule that inhibits ERK1 MAPK3 and RasGAP. It also inhibits RSK1, RSK2, RSK3, and RSK4 with IC50s of 0.5, 2.5, 3.3, and 10.0 μM, respectively (52). MAPK3 was increased more than 1.6-fold in PC9GR cells while RASA1 had no differential expression. In CCLE lung cell line data, pluripotin's response was associated with the expression of F3, AXL, PDCD1LG2, and CD274, and these genes were highly expressed in PC9GR cells. Although its inhibitory effect for PC9GR cells was not as strong as for PC9 cells, it had a synergistic effect when combined with gefitinib (Figure S2). Further evaluation of its combination may clarify its potential.

For gene expression, our data recapitulated some previous reports. AXL was significantly increased, and MAPK1, VIM, GAS6, NFKB1, and KDM5A were slightly increased in our data. Interleukin-6 was identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells (43). Our data also show that the hypoxia pathway was significantly enriched, and IL6 had about a 2-fold increase in PC9GR cells. On the other hand, some genes reported no change in PC9GR cells. For example, NFKB1 is reported to be upregulated as an early event of TKI resistance (42); however, for the cells with long exposure to gefitinib with stable resistance, this gene was not activated and was significantly decreased more than 1.5-fold in PC9GR cells. FGF2 was not significantly changed although FGFR1 was increased about 1.8-fold (39). The discrepancies could be the results of tumor heterogeneities and experimental conditions. Literature reports are from different groups and different sets of tumors or cell lines. For the same PC9 cell line, our resistance line was established after long-term (12 months) exposure to gefitinib while other groups profiled resistant cells established at 1.5 or 6 months (38).

Our study found several interesting genes not reported in TKI-resistant cells before. BASP1 was one of the most upregulated genes in PC9GR cells, yet its functions are largely unknown. Some studies have showed it is a tumor suppressor, and restoration of its expression in cancer cells inhibits tumor growth and migration for thyroid cancer (53). High expression of this gene is associated with better patient survival in breast cancer (54) and pancreatic cancer in which better response to adjuvant chemotherapy is also observed (55). On the other hand, studies found that this gene promoted cancer growth and was a poor prognostic factor in cervical cancer (56). The roles and functions of BASP1 are likely cancer type and context specific. COL6A2 is another gene significantly upregulated in PC9GR cells, and previous reports showed that increased expression of multiple collagen genes, including COL6A2 was associated with drug resistance, tumor metastasis, and poor patient survival in ovarian cancer (57, 58).

Mechanisms of resistance to TKIs are complicated and multifold (59). Through gene expression profiling, a previous study reported the increased activity of autophagy mediated by ERK and AKT activation in resistant cells (60). Cellular proliferation, apoptosis, and cell cycle were also involved (61). Although our study has overlap with these reports, differences exist, such as some top regulated genes reported had no change or opposite changes in our study (CDKN2B was found to be up-expressed, but it was down in resistant cells in our study). These differences highlight the heterogeneity of cell lines, and resistant mechanisms may diverge according to exposure conditions.

Because of these complexities, clinical management for resistance tumors needs a combination strategy targeting multiple pathways or genes. Chemo-drug combinations can have a synergistic effect. For example, we tried the combination of gefitinib with either dasatinib or pluripotin, and both showed synergistic effects at certain concentration combinations with combination index (CI) <1 (Figure S2). We did not evaluate the synergistic effect of KPT-185 as it already had a very strong inhibitory effect on PC9GR cells; however, its combination with other drugs might even be more effective in the treatment of EGFR-TKI-resistant lung cancer, which is one of our future plans.

In spite of the interesting findings, our conclusions are from a single lung cancer cell line, which may or may not be generalizable to other cell lines. Future studies need to include more cell lines with different mutation status. Additionally, our drug response data are limited to in vitro cell lines, and studies are needed in vivo or clinical trials to translate the findings.

Conclusions

In conclusion, our study shows that acquired TKI-resistant lung cancer cells (PC9GR) have significantly altered the transcription and pathway regulation for new therapeutic targets. Existing drugs may be reused to treat patients who are resistant to TKIs.

Data Availability Statement

The original contributions presented in the study are publicly available. This data can be found here: the NCBI Gene Expression Omnibus (GSE129221).

Author Contributions

NW and ZS contributed to the study design, data analysis, and manuscript writing. YS and FZ contributed to materials and analysis. XZ contributed to the design and revised the manuscript critically. All authors read and approved the final manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Glossary

Abbreviations

EGFR

epidermal growth factor receptor

TKIs

tyrosine kinase inhibitors

CCLE

cancer cell line encyclopedia

CTRP

Cancer Therapeutics Response Portal

NSCLC

non-small cell lung cancer

EMT

epithelial-to-mesenchymal transition

RNA-seq

RNA sequencing

FDR

false discovery rate

FPKM

fragments per kilobase million

DEGs

differentially expressed genes

RITAN

rapid integration of term annotation

STAR

spliced transcripts alignment to a reference

IPA

ingenuity pathway analysis

RPKM

reads per kilobase million

GEO

gene expression omnibus

IC50

half maximal inhibitory concentration

PCA

principal components analysis

KEGG

kyoto encyclopedia of genes and genomes

CML

chronic myelogenous leukemia.

Footnotes

Funding. This work was supported by the National Natural Science Foundation of China (Grant No. 81670091).

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.01424/full#supplementary-material

Figure S1

Apoptotic effect of KPT-185 on PC9 and PC9GR.

Click here for additional data file. (580.8KB, PDF)
Figure S2

Inhibition effects of drug combinations.

Click here for additional data file. (580.8KB, PDF)
Table S1

Differentially expressed genes (n = 864) between resistant and sensitive lung cancer cells.

Click here for additional data file. (166.9KB, XLSX)
Table S2

Upregulated genes in resistant cells and their available targeting drugs.

Click here for additional data file. (12.5KB, XLSX)

References

  • 1.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. (2015) 65:87–108. 10.3322/caac.21262 [DOI] [PubMed] [Google Scholar]
  • 2.Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. (2010) 7:493–507. 10.1038/nrclinonc.2010.97 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res. (2006) 12:7242–51. 10.1158/1078-0432.CCR-06-0646 [DOI] [PubMed] [Google Scholar]
  • 4.Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med. (2009) 361:1018–20. 10.1056/NEJMe0905763 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. (2004) 304:1497–500. 10.1126/science.1099314 [DOI] [PubMed] [Google Scholar]
  • 6.Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. (2004) 101:13306–11. 10.1073/pnas.0405220101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zhou CC, Wu YL, Chen GY, Feng JF, Liu XQ, Wang CL, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. (2011) 12:735–42. 10.1016/S1470-2045(11)70184-X [DOI] [PubMed] [Google Scholar]
  • 8.Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. (2012) 13:239–46. 10.1016/S1470-2045(11)70393-X [DOI] [PubMed] [Google Scholar]
  • 9.Hammerman PS, Janne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. (2009) 15:7502–9. 10.1158/1078-0432.CCR-09-0189 [DOI] [PubMed] [Google Scholar]
  • 10.Stewart EL, Tan SZ, Liu G, Tsao MS. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res. (2015) 4:67–81. 10.3978/j.issn.2218-6751.2014.11.06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. (2011) 17:1616–22. 10.1158/1078-0432.CCR-10-2692 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. (2011) 3:75ra26. 10.1126/scitranslmed.3002003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. (2011) 17:1169–80. 10.1158/1078-0432.CCR-10-2277 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. (2006) 12:6494–501. 10.1158/1078-0432.CCR-06-1570 [DOI] [PubMed] [Google Scholar]
  • 15.Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res. (2008) 14:7519–25. 10.1158/1078-0432.CCR-08-0151 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. (2007) 316:1039–43. 10.1126/science.1141478 [DOI] [PubMed] [Google Scholar]
  • 17.Kubo N, Harada T, Shiraishi Y, Nosaki K, Nakagaki N, Takeshita M, et al. Identification of genomic alterations acquired during treatment with egfr-tkis in non-small cell lung cancer. Anticancer Res. (2019) 39:671–7. 10.21873/anticanres.13162 [DOI] [PubMed] [Google Scholar]
  • 18.Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. (2012) 2:922–33. 10.1158/2159-8290.CD-12-0108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ma P, Fu Y, Chen M, Jing Y, Wu J, Li K, et al. Adaptive and acquired resistance to EGFR inhibitors converge on the MAPK pathway. Theranostics. (2016) 6:1232–43. 10.7150/thno.14409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lu Y, Liu Y, Oeck S, Glazer PM. Hypoxia promotes resistance to EGFR inhibition in NSCLC cells via the histone demethylases, LSD1 and PLU-1. Mol Cancer Res. (2018) 16:1458–69. 10.1158/1541-7786.MCR-17-0637 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wang L, Dong X, Ren Y, Luo J, Liu P, Su D, et al. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death Dis. (2018) 9:129. 10.1038/s41419-017-0120-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. (2005) 65:9455–62. 10.1158/0008-5472.CAN-05-1058 [DOI] [PubMed] [Google Scholar]
  • 23.Rho JK, Choi YJ, Lee JK, Ryoo BY, Na, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer. (2009) 63:219–26. 10.1016/j.lungcan.2008.05.017 [DOI] [PubMed] [Google Scholar]
  • 24.Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol. (2011) 6:1152–61. 10.1097/JTO.0b013e318216ee52 [DOI] [PubMed] [Google Scholar]
  • 25.Zhang X, Liu G, Kang Y, Dong Z, Qian Q, Ma X. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS ONE. (2013) 8:e57692. 10.1371/journal.pone.0057692 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. (2012) 44:852–60. 10.1038/ng.2330 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. (2013) 19:279–90. 10.1158/1078-0432.CCR-12-1558 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature. (2011) 471:523–6. 10.1038/nature09870 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. (2010) 141:69–80. 10.1016/j.cell.2010.02.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Song YA, Ma T, Zhang XY, Cheng XS, Olajuyin AM, Sun ZF, et al. Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway. Cancer Cell Int. (2019) 19:117. 10.1186/s12935-019-0836-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. (2015) 43:e47. 10.1093/nar/gkv007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Zimmermann MT, Kabat B, Grill DE, Kennedy RB, Poland GA. RITAN: rapid integration of term annotation and network resources. PeerJ. (2019) 7:e6994. 10.7717/peerj.6994 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sun Z, Bhagwate A, Prodduturi N, Yang P, Kocher JA. Indel detection from RNA-seq data: tool evaluation and strategies for accurate detection of actionable mutations. Brief Bioinform. (2017) 18:973–83. 10.1093/bib/bbw069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. (2013) 29:15–21. 10.1093/bioinformatics/bts635 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T, et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line. Cancer Res. (2007) 67:7807–14. 10.1158/0008-5472.CAN-07-0681 [DOI] [PubMed] [Google Scholar]
  • 36.Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. (2010) 29:2346–56. 10.1038/onc.2009.526 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, et al. NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. (2015) 11:98–110. 10.1016/j.celrep.2015.03.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. (2016) 22:262–9. 10.1038/nm.4040 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. (2013) 2:e39. 10.1038/oncsis.2013.4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. (2014) 74:253–62. 10.1158/0008-5472.CAN-13-1103 [DOI] [PubMed] [Google Scholar]
  • 41.Tian Y, Zhang Z, Miao L, Yang Z, Yang J, Wang Y, et al. Anexelekto (AXL) increases resistance to EGFR-TKI and activation of AKT and ERK1/2 in non-small cell lung cancer cells. Oncol Res. (2016) 24:295–303. 10.3727/096504016X14648701447814 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Fukuoka M, Yoshioka K, Hohjoh H. NF-kappaB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells. PLoS ONE. (2018) 13:e0201796. 10.1371/journal.pone.0201796 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.An SM, Lei HM, Ding XP, Sun F, Zhang C, Tang YB, et al. Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells. Oncol Lett. (2017) 14:3445–54. 10.3892/ol.2017.6613 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bertolo C, Sainz C, et al. YES1 drives lung cancer growth and progression and predicts sensitivity to Dasatinib. Am J Respir Crit Care Med. (2019) 200:888–99. 10.1164/rccm.201807-1292OC [DOI] [PubMed] [Google Scholar]
  • 45.Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, et al. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci USA. (2018) 115:E6030–8. 10.1101/275974 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. (2012) 120:1765–73. 10.1182/blood-2012-04-423160 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, et al. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology. (2013) 144:447–56. 10.1053/j.gastro.2012.10.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wang S, Han X, Wang J, Yao J, Shi Y. Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. PLoS ONE. (2014) 9:e89848. 10.1371/journal.pone.0089848 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Ferreira BI, Cautain B, Grenho I, Link W. Small molecule inhibitors of CRM1. Front Pharmacol. (2020) 11:625. 10.3389/fphar.2020.00625 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Wang AY, Liu H. The past, present, and future of CRM1/XPO1 inhibitors. Stem Cell Investig. (2019) 6:6. 10.21037/sci.2019.02.03 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Kauffman M, Sun H, Shacham S, Hattori N, Chien W, Sudo M, et al. KPT-330 has antitumour activity against non-small cell lung cancer. Br J Cancer. (2014) 111:281–91. 10.1038/bjc.2014.260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Mertins SD, Scudiero DA, Hollingshead MG, Divelbiss RD, Jr, Alley MC, Monks A, et al. A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept. PLoS ONE. (2013) 8:e57099. 10.1371/journal.pone.0057099 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Guo RS, Yu Y, Chen J, Chen YY, Shen N, Qiu M. Restoration of brain acid soluble protein 1 inhibits proliferation and migration of thyroid cancer cells. Chin Med J. (2016) 129:1439–46. 10.4103/0366-6999.183434 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Marsh LA, Carrera S, Shandilya J, Heesom KJ, Davidson AD, Medler KF, et al. BASP1 interacts with oestrogen receptor alpha and modifies the tamoxifen response. Cell Death Dis. (2017) 8:e2771. 10.1038/cddis.2017.179 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Zhou Q, Andersson R, Hu D, Bauden M, Kristl T, Sasor A, et al. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue. EBioMedicine. (2019) 43:282–94. 10.1016/j.ebiom.2019.04.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Tang H, Wang Y, Zhang B, Xiong S, Liu L, Chen W, et al. High brain acid soluble protein 1(BASP1) is a poor prognostic factor for cervical cancer and promotes tumor growth. Cancer Cell Int. (2017) 17:97. 10.1186/s12935-017-0452-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, et al. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. (2014) 20:711–23. 10.1158/1078-0432.CCR-13-1256 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Januchowski R, Swierczewska M, Sterzynska K, Wojtowicz K, Nowicki M, Zabel M. Increased expression of several collagen genes is associated with drug resistance in ovarian cancer cell lines. J Cancer. (2016) 7:1295–310. 10.7150/jca.15371 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. (2016) 1:e000060. 10.1136/esmoopen-2016-000060 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Qi M, Tian Y, Li W, Li D, Zhao T, Yang Y, et al. ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells. Oncotarget. (2018) 9:12020–34. 10.18632/oncotarget.24147 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Lee TG, Jeong EH, Min IJ, Kim SY, Kim HR, Kim CH. Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors. Oncol Lett. (2017) 14:2191–7. 10.3892/ol.2017.6428 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure S1

Apoptotic effect of KPT-185 on PC9 and PC9GR.

Click here for additional data file. (580.8KB, PDF)
Figure S2

Inhibition effects of drug combinations.

Click here for additional data file. (580.8KB, PDF)
Table S1

Differentially expressed genes (n = 864) between resistant and sensitive lung cancer cells.

Click here for additional data file. (166.9KB, XLSX)
Table S2

Upregulated genes in resistant cells and their available targeting drugs.

Click here for additional data file. (12.5KB, XLSX)

Data Availability Statement

The original contributions presented in the study are publicly available. This data can be found here: the NCBI Gene Expression Omnibus (GSE129221).

Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES